{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:36:44Z","timestamp":1790793404496,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Shriners Hospital Postdoctoral Fellowship","award":["#84206"],"award-info":[{"award-number":["#84206"]}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["#BALLOK15F0"],"award-info":[{"award-number":["#BALLOK15F0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shriners","award":["#8770"],"award-info":[{"award-number":["#8770"]}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["#11P0"],"award-info":[{"award-number":["#11P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R33AI105902"],"award-info":[{"award-number":["R33AI105902"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R56AI063433"],"award-info":[{"award-number":["R56AI063433"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.mib.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T08:41:47Z","timestamp":1466152907000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["Considerations and caveats in anti-virulence drug development"],"prefix":"10.1016","volume":"33","author":[{"given":"Damien","family":"Maura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia E","family":"Ballok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence G","family":"Rahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2016.06.001_bib0350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/MMBR.00039-14","article-title":"Origin and proliferation of multiple-drug resistance in bacterial pathogens","volume":"79","author":"Chang","year":"2015","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.mib.2016.06.001_bib0355","unstructured":"http:\/\/www.cdc.gov\/drugresistance\/pdf\/carb_national_strategy.pdf."},{"key":"10.1016\/j.mib.2016.06.001_sbref0360","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","article-title":"Alternatives to antibiotics-a pipeline portfolio review","volume":"16","author":"Czaplewski","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mib.2016.06.001_bib0365","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.mib.2016.06.001_bib0370","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nature00802","article-title":"Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis","volume":"417","author":"Shankar","year":"2002","journal-title":"Nature"},{"issue":"Suppl 5","key":"10.1016\/j.mib.2016.06.001_bib0375","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2016.06.001_bib0380","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1469-0691.2007.01840.x","article-title":"Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci","volume":"14","author":"Sakka","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mib.2016.06.001_bib0385","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2016.06.001_bib0390","first-page":"335","article-title":"Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients","volume":"46","author":"Karabay","year":"2012","journal-title":"Mikrobiyol Bul"},{"key":"10.1016\/j.mib.2016.06.001_bib0395","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.02643-14","article-title":"A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models","volume":"58","author":"Warrener","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.06.001_bib0400","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00253-011-3122-9","article-title":"Menthol diminishes Staphylococcus aureus virulence-associated extracellular proteins expression","volume":"90","author":"Qiu","year":"2011","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.mib.2016.06.001_bib0405","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1371\/journal.ppat.0030126","article-title":"Inhibitors of pathogen intercellular signals as selective anti-infective compounds","volume":"3","author":"Lesic","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.06.001_sbref0410","doi-asserted-by":"crossref","first-page":"e1004321","DOI":"10.1371\/journal.ppat.1004321","article-title":"Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity","volume":"10","author":"Starkey","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.06.001_bib0415","doi-asserted-by":"crossref","first-page":"e36312","DOI":"10.1371\/journal.pone.0036312","article-title":"Chemical inhibition of bacterial protein tyrosine phosphatase suppresses capsule production","volume":"7","author":"Standish","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mib.2016.06.001_sbref0420","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1021\/jm9001764","article-title":"Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results","volume":"52","author":"Song","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_bib0425","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1039\/b817926c","article-title":"Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates","volume":"7","author":"Huigens","year":"2009","journal-title":"Org Biomol Chem"},{"issue":"Pt 5","key":"10.1016\/j.mib.2016.06.001_bib0430","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1099\/jmm.0.038638-0","article-title":"Garlic ointment inhibits biofilm formation by bacterial pathogens from burn wounds","volume":"61","author":"Nidadavolu","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0435","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1007\/s00253-014-5903-4","article-title":"Anti-biofilm, anti-hemolysis, and anti-virulence activities of black pepper, cananga, myrrh oils, and nerolidol against Staphylococcus aureus","volume":"98","author":"Lee","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.mib.2016.06.001_bib0440","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fmicb.2012.00144","article-title":"Honey's ability to counter bacterial infections arises from both bactericidal compounds and QS inhibition","volume":"3","author":"Wang","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0445","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8030072","article-title":"Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy","volume":"8","author":"Kong","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.mib.2016.06.001_bib0450","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jam.12743","article-title":"Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self-assembly of alpha-hemolysin","volume":"118","author":"Wang","year":"2015","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0455","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1517\/14656561003724747","article-title":"Needed, new paradigms in antibiotic development","volume":"11","author":"Ceri","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.mib.2016.06.001_bib0460","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/fmc.15.7","article-title":"Agents that inhibit bacterial biofilm formation","volume":"7","author":"Rabin","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_bib0465","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1002\/anie.200800862","article-title":"Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing bacterial biofilms across order, class, and phylum","volume":"47","author":"Rogers","year":"2008","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.mib.2016.06.001_bib0470","doi-asserted-by":"crossref","first-page":"16707","DOI":"10.3390\/molecules191016707","article-title":"Evaluation of the toxicity of 5-aryl-2-aminoimidazole-based biofilm inhibitors against eukaryotic cell lines, bone cells and the nematode Caenorhabditis elegans","volume":"19","author":"Steenackers","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.mib.2016.06.001_bib0475","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3389\/fmicb.2015.01031","article-title":"The therapeutic effect of chlorogenic acid against Staphylococcus aureus infection through sortase A inhibition","volume":"6","author":"Wang","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0480","doi-asserted-by":"crossref","first-page":"L352","DOI":"10.1152\/ajplung.00387.2012","article-title":"Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia","volume":"305","author":"Bucior","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0485","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1021\/jm500215s","article-title":"Targeting Staphylococcus aureus quorum sensing with nonpeptidic small molecule inhibitors","volume":"57","author":"Murray","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_bib0490","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/cb400485k","article-title":"High-throughput screening using the differential radial capillary action of ligand assay identifies ebselen as an inhibitor of diguanylate cyclases","volume":"9","author":"Lieberman","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2016.06.001_bib0495","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1462-5822.2006.00877.x","article-title":"Inhibitors of bacterial virulence identified in a surrogate host model","volume":"9","author":"Benghezal","year":"2007","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0500","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrmicro2199","article-title":"The type III secretion system of Pseudomonas aeruginosa: infection by injection","volume":"7","author":"Hauser","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0505","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1039\/C2MD20213A","article-title":"Small molecules aimed at type III secretion systems to inhibit bacterial virulence","volume":"4","author":"Tsou","year":"2013","journal-title":"Medchemcomm"},{"key":"10.1016\/j.mib.2016.06.001_bib0510","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/1087057111408605","article-title":"Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei","volume":"16","author":"Moir","year":"2011","journal-title":"J Biomol Screen"},{"issue":"Pt 9","key":"10.1016\/j.mib.2016.06.001_bib0515","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1099\/mic.0.079616-0","article-title":"Characterization of a novel two-partner secretion system implicated in the virulence of Pseudomonas aeruginosa","volume":"160","author":"Faure","year":"2014","journal-title":"Microbiology"},{"key":"10.1016\/j.mib.2016.06.001_bib0520","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2008.08.001","article-title":"An inhibitor of gram-negative bacterial virulence protein secretion","volume":"4","author":"Felise","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mib.2016.06.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b01698","article-title":"Novel strategies for the treatment of Pseudomonas aeruginosa infections","author":"Wagner","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_bib0530","first-page":"307","article-title":"Interaction between the pili of Pseudomonas aeruginosa PAK and its carbohydrate receptor beta-d-GalNAc(1-->4)beta-D-Gal analogs","volume":"44","author":"Schweizer","year":"1998","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MMBR.00043-12","article-title":"Cyclic di-GMP: the first 25 years of a universal bacterial second messenger","volume":"77","author":"Romling","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.mib.2016.06.001_bib0540","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-014-0100-x","article-title":"The hierarchy quorum sensing network in Pseudomonas aeruginosa","volume":"6","author":"Lee","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.mib.2016.06.001_bib0545","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.1073\/pnas.1316981110","article-title":"A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation","volume":"110","author":"O\u2019Loughlin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mib.2016.06.001_bib0550","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1021\/ja903292v","article-title":"Covalent inhibition of bacterial quorum sensing","volume":"131","author":"Amara","year":"2009","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2016.06.001_bib0555","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1093\/emboj\/cdg366","article-title":"Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors","volume":"22","author":"Hentzer","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.mib.2016.06.001_sbref0560","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ismej.2011.122","article-title":"Quorum quenching quandary: resistance to antivirulence compounds","volume":"6","author":"Maeda","year":"2012","journal-title":"ISME J"},{"key":"10.1016\/j.mib.2016.06.001_bib0565","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1038\/srep07245","article-title":"Non-antibiotic quorum sensing inhibitors acting against N-acyl homoserine lactone synthase as druggable target","volume":"4","author":"Chang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2016.06.001_bib0570","doi-asserted-by":"crossref","first-page":"e1003024","DOI":"10.1371\/journal.ppat.1003024","article-title":"The quorum sensing volatile molecule 2-amino acetophenon modulates host immune responses in a manner that promotes life with unwanted guests","volume":"8","author":"Bandyopadhaya","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.06.001_bib0575","doi-asserted-by":"crossref","first-page":"e1002192","DOI":"10.1371\/journal.ppat.1002192","article-title":"A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes","volume":"7","author":"Kesarwani","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.06.001_bib0580","doi-asserted-by":"crossref","first-page":"e1003508","DOI":"10.1371\/journal.ppat.1003508","article-title":"Structural basis for native agonist and synthetic inhibitor recognition by the Pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR)","volume":"9","author":"Ilangovan","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.06.001_bib0585","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1021\/cb300208g","article-title":"Identification of small-molecule antagonists of the Pseudomonas aeruginosa transcriptional regulator PqsR: biophysically guided hit discovery and optimization","volume":"7","author":"Klein","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2016.06.001_bib0590","doi-asserted-by":"crossref","first-page":"16143","DOI":"10.1021\/ja3072397","article-title":"Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors","volume":"134","author":"Storz","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2016.06.001_bib0595","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cbic.201100014","article-title":"Biosynthesis of 2-Alkyl-4(1H)-quinolones in Pseudomonas aeruginosa: potential for therapeutic interference with pathogenicity","volume":"12","author":"Pistorius","year":"2011","journal-title":"Chembiochem"},{"key":"10.1016\/j.mib.2016.06.001_bib0600","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejmech.2014.11.055","article-title":"Catechol-based substrates of chalcone synthase as a scaffold for novel inhibitors of PqsD","volume":"90","author":"Allegretta","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_sbref0605","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nature12790","article-title":"Activated ClpP kills persisters and eradicates a chronic biofilm infection","volume":"503","author":"Conlon","year":"2013","journal-title":"Nature"},{"issue":"Pt 11","key":"10.1016\/j.mib.2016.06.001_bib0610","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1099\/mic.0.27954-0","article-title":"The LuxR receptor: the sites of interaction with quorum-sensing signals and inhibitors","volume":"151","author":"Koch","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.mib.2016.06.001_bib0615","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1128\/AEM.02378-13","article-title":"Resistance to quorum-quenching compounds","volume":"79","author":"Garcia-Contreras","year":"2013","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0620","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1021\/cb5004288","article-title":"Competition studies confirm two major barriers that can preclude the spread of resistance to quorum-sensing inhibitors in bacteria","volume":"9","author":"Gerdt","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2016.06.001_bib0625","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00131-11","article-title":"The sociomicrobiology of antivirulence drug resistance: a proof of concept","volume":"2","author":"Mellbye","year":"2011","journal-title":"MBio"},{"key":"10.1016\/j.mib.2016.06.001_bib0630","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/emph\/eou003","article-title":"Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment","volume":"2014","author":"Ross-Gillespie","year":"2014","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.mib.2016.06.001_bib0635","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.1153018","article-title":"A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence","volume":"319","author":"Liu","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.mib.2016.06.001_bib0640","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrmicro3232","article-title":"Targeting virulence: can we make evolution-proof drugs?","volume":"12","author":"Allen","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2016.06.001_bib0645","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.suc.2014.08.008","article-title":"Surgical site infections","volume":"94","author":"Young","year":"2014","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.mib.2016.06.001_bib0650","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2174\/1568026615666150414123800","article-title":"Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections","volume":"15","author":"Mihai","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.mib.2016.06.001_bib0655","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4046\/trd.2016.79.2.53","article-title":"Sepsis and acute respiratory distress syndrome: recent update","volume":"79","author":"Kim","year":"2016","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.mib.2016.06.001_bib0660","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.mib.2016.06.001_bib0665","series-title":"KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas aeruginosa Lung Infections in Cystic Fibrosis Patients","year":"2015"},{"key":"10.1016\/j.mib.2016.06.001_bib0670","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mib.2016.06.001_bib0675","unstructured":"https:\/\/www.medimmune.com\/our-therapy-areas\/infectious-disease-vaccines.html."},{"key":"10.1016\/j.mib.2016.06.001_bib0680","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7150\/ijms.5.371","article-title":"Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients","volume":"5","author":"Hauber","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.mib.2016.06.001_bib0685","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/SLA.0000000000000759","article-title":"Prediction of multiple infections after severe burn trauma: a prospective cohort study","volume":"261","author":"Yan","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.mib.2016.06.001_sbref0690","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jama.2015.19417","article-title":"Integrating predictive analytics into high-value care: the dawn of precision delivery","volume":"315","author":"Parikh","year":"2016","journal-title":"JAMA"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527416300819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527416300819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T19:08:17Z","timestamp":1572462497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527416300819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":69,"alternative-id":["S1369527416300819"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2016.06.001","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations and caveats in anti-virulence drug development","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}